Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label grazoprevir/elbasvir (MK-5172/MK-8742). Show all posts
Showing posts with label grazoprevir/elbasvir (MK-5172/MK-8742). Show all posts
Thursday, April 14, 2016

ILC2016 Head-to-head study: once daily oral combination of elbasvir and grazoprevir versus sofosbuvir and pegylated interferon alpha 2b + ribavirin

›
  Newly approved all-oral Hepatitis C combination drug found more effective in a head-to-head comparison April 14, 2016 Press Releases Head...
Thursday, January 28, 2016

Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review

›
ZEPATIER - Recommended Dosage and Durations, Drug Interactions, Side Effects, Clinical Studies Prescribing Information for ZEPATIER Patie...
Tuesday, November 10, 2015

Grazoprevir, Elbasvir Combination Effective for Patients With Hepatitis C, Kidney Disease: Presented at Kidney Week

›
Grazoprevir, Elbasvir Combination Effective for Patients With Hepatitis C, Kidney Disease: Presented at Kidney Week By Nancy A. Melville So...
Tuesday, October 20, 2015

Merck to Present New Data on HCV Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015

›
Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase ...
Tuesday, September 29, 2015

Full Text: HCV targeting of patients with cirrhosis

›
October 2015 Volume 63, Issue 4, Pages 1015–1022 HCV targeting of patients with cirrhosis Peter Ferenci, Karin Kozbial , M...
Saturday, September 19, 2015

Hepatitis C-Salvage Study Grazoprevir and Elbasvir Plus Ribavirin: Final 24-week Follow-up Results

›
C-SALVAGE: Final 24-week Follow-up Results Posted on September 17, 2015 Non-cross-resistant drugs are needed for salvage therapy of patie...